

Reference:	FOI.17081.25
Subject:	Medications
Date of Request:	11 April 2025

Requested:

1. How many patients have been treated (for any condition) in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:
 - Age 6-11
 - Age 12-17
 - Age 18 and above

3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:
 - Dupilumab
 - Omalizumab

4. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients within Secondary Care that have been treated for any condition with the listed medications, during the period 1 December 2024 to 31 March 2025.

Medication	Number
Benralizumab	90
Dupilumab	118
Omalizumab	19
Reslizumab	0

Mepolizumab	30
Tezepelumab	88

2. The UHB provides, within the table below, the number of patients within Secondary Care that received the medications listed in question 1, by the age ranges 6 to 11, 12 to 17 and 18 and over, during the period 1 December 2024 to 31 March 2025.

Age range	Number
6 to 11	7
12-17	8
18 and over	328

3. The UHB provides, within the table below, the number of respiratory patients within Secondary Care that have been treated with the medications listed, during the period 1 December 2024 to 31 March 2025.

Medication	Number
Dupilumab	11
Omalizumab	0

4. The UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.